NeoTract, Inc. Announces Excellent Data From Two Studies of the Minimally Invasive UroLift System Treatment for Enlarged Prostate
NeoTract Announces Positive Guidelines from European Association of Urology for Minimally Invasive Treatment for Benign Prostatic Hyperplasia
NeoTract, Inc. Announces Publication Showing Sustained Safety and Efficacy Benefits for the Minimally Invasive UroLift® System Treatment for Enlarged Prostate
Urology Times SupplementUroLift® System Treatment: Expert Panel Discussion
Perito Urology is NeoTract’s First UroLift® System Training Center of Excellence in the U.S.
NeoTract Announces Aetna US Healthcare and Coventry Health Care Positive Coverage Decision Regarding UroLift® Implant Procedure for Men with Enlarged Prostate
NeoTract’s UroLift® Implant Procedure for Men with Enlarged
Prostate Receives Medicare and Medicaid Outpatient Billing Codes for Reimbursement
NICE gives go ahead to NeoTract’s groundbreaking UroLift® Prostate Implant that can preserve sexual function while offering urinary symptom relief for millions of men affected by enlarged prostates
First U.S. Patient Treated Following FDA Clearance of NeoTract's UroLift® System
NeoTract, Inc. Receives U.S. FDA De Novo Approval for the UroLift® Prostate Implant
NeoTract's UroLift® Prostate Implant Demonstrates Strong Safety and Efficacy Benefits with Minimally Invasive BPH Treatment
© Copyright 2012–2015 NeoTract, Inc. Alle Rechte Vorbehalten.